Clinical trials
Phase 1 Myositis trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
57 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2014 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2023 | 3 |
| 2024 | 12 |
| 2025 | 24 |
| 2026 | 14 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 28 |
| Not yet recruiting | 9 |
| Withdrawn | 4 |
| Active, not recruiting | 4 |
| Terminated | 3 |
| Unknown status | 3 |
| Completed | 2 |
| Suspended | 2 |
| Enrolling by invitation | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| China Immunotech (Beijing) Biotechnology Co., Ltd. | 5 |
| Nanjing Bioheng Biotech Co., Ltd. | 3 |
| Tongji Hospital | 3 |
| AstraZeneca | 2 |
| Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 2 |
| Nanjing Legend Biotech Co. | 2 |
| PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2 |
| RenJi Hospital | 2 |
| Adicet Therapeutics | 1 |
| Allogene Therapeutics | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Myositis | 57 |
| Lupus Erythematosus, Systemic | 40 |
| Scleroderma, Systemic | 35 |
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 22 |
| Autoimmune Diseases | 15 |
| Sjogren's Syndrome | 15 |
| Arthritis, Rheumatoid | 14 |
| Lupus Nephritis | 12 |
| Antiphospholipid Syndrome | 8 |
| Scleroderma, Diffuse | 8 |
Trials
Showing 1 to 25 of 57. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.